Metoprolol is NOT an ACE Inhibitor
No, metoprolol is a beta-1 selective (cardioselective) adrenergic receptor blocker, not an angiotensin-converting enzyme (ACE) inhibitor. These are two completely different drug classes with distinct mechanisms of action 1.
Drug Classification
Metoprolol belongs to the beta-blocker class of medications. Specifically, it is:
- A beta-1 selective adrenergic receptor blocker that preferentially blocks cardiac beta-1 receptors 1
- Classified among cardioselective beta-blockers in major hypertension guidelines 2
- Works by reducing heart rate, cardiac output, and myocardial oxygen demand through competitive antagonism of catecholamines 1
How Metoprolol Differs from ACE Inhibitors
Mechanism of Action:
- Metoprolol: Blocks beta-1 adrenergic receptors in the heart, reducing heart rate and contractility 1
- ACE Inhibitors: Block the conversion of angiotensin I to angiotensin II and prevent bradykinin degradation 3, 4
Metabolic Pathway:
- Metoprolol is primarily metabolized by CYP2D6 in the liver 1
- ACE inhibitors work on the renin-angiotensin system 4
Clinical Use Context
Both drug classes are used for hypertension management but through different pathways 2. In fact, they are frequently combined in clinical practice:
- Beta-blockers like metoprolol are often added as second-line therapy when ACE inhibitors alone don't adequately control blood pressure 5
- The combination is particularly common in diabetic patients with hypertension 6, 5
- Studies show consistent benefit when metoprolol is combined with various doses of ACE inhibitors in heart failure 7
Important Clinical Distinction
Common Pitfall: Do not confuse beta-blockers with ACE inhibitors when prescribing or counseling patients, as they have different: